Literature DB >> 24921644

Myofibromas with atypical features: expanding the morphologic spectrum of a benign entity.

Konstantinos Linos1, Jodi M Carter, Jerad M Gardner, Andrew L Folpe, Sharon W Weiss, Mark A Edgar.   

Abstract

Typical myofibromas are biphasic tumors composed of a central zone of immature spindled to rounded cells arranged in a pericytic pattern and a peripheral zone of myoid nodules. Central necrosis is occasionally seen. A small but undefined subset of myofibromas displays atypical features that may lead to a misdiagnosis of sarcoma. To more completely characterize these tumors and define their behavior, we analyzed our experience with myofibromas having 1 or more atypical features including hypercellularity, absent or inconspicuous, poorly demarcated myoid nodules, infiltrative growth pattern, and perineural invasion. Of 266 cases of myofibromas, 24 cases were retrieved on the basis of pathology reports in which atypical features were mentioned. The tumors presented in 16 male and 8 female individuals (mean age 17 y; range, 2 wk to 62 y) as masses of variable size (mean 3.0 cm; range, 1.5 to 6.5 cm). Fourteen cases arose on the head and neck and 10 cases on the limbs. The referring or suspected diagnosis was sarcoma in 8 cases. The tumors were typically more cellular than ordinary myofibroma with levels of cellularity similar to that expected in fibrosarcoma (22/24). In addition, they displayed inconspicuous, loosely cohesive (22/24) or absent myoid nodules (2/24), infiltrating borders (19/24), intravascular growth (5/24), and perineural invasion/nerve entrapment (6/24). The mean mitotic rate was 5 mitoses/10 high-power fields, but no tumor showed significant cytologic atypia. The tumors were positive for actins (11/11) and CD34 (2/8). Follow-up in 14 patients revealed no distant metastases. We conclude that a small subset of myofibromas shows atypical features that complicate the diagnosis but do not adversely affect outcome.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24921644     DOI: 10.1097/PAS.0000000000000270

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  7 in total

1.  Recurrent SRF-RELA Fusions Define a Novel Subset of Cellular Myofibroma/Myopericytoma: A Potential Diagnostic Pitfall With Sarcomas With Myogenic Differentiation.

Authors:  Cristina R Antonescu; Yun-Shao Sung; Lei Zhang; Narasimhan P Agaram; Christopher D Fletcher
Journal:  Am J Surg Pathol       Date:  2017-05       Impact factor: 6.394

Review 2.  What is new in pericytomatous, myoid, and myofibroblastic tumors?

Authors:  Ivy John; Karen J Fritchie
Journal:  Virchows Arch       Date:  2019-11-08       Impact factor: 4.064

3.  TFG-MET fusion in an infantile spindle cell sarcoma with neural features.

Authors:  Uta Flucke; Max M van Noesel; Marc Wijnen; Lei Zhang; Chun-Liang Chen; Yun-Shao Sung; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2017-06-27       Impact factor: 5.006

4.  Fibroma of tendon sheath is defined by a USP6 gene fusion-morphologic and molecular reappraisal of the entity.

Authors:  Jože Pižem; Alenka Matjašič; Andrej Zupan; Boštjan Luzar; Daja Šekoranja; Katarina Dimnik
Journal:  Mod Pathol       Date:  2021-06-04       Impact factor: 7.842

5.  A rare erosive orbital mass in a child: Case report of myofibroma.

Authors:  Bahram Eshraghi; Shima Dehghani; Ghasem Saeedi-Anari
Journal:  J Curr Ophthalmol       Date:  2017-05-04

6.  Myofibroma as a Rapidly Growing Gingival Mass in a 4-year-old Boy: a Case Report.

Authors:  Saede Atarbashi-Moghadam; Ali Lotfi; Shokoufeh Shahrabi-Farahani; Fazele Atarbashi-Moghadam
Journal:  J Dent (Shiraz)       Date:  2018-06

7.  Genetic testing and surveillance in infantile myofibromatosis: a report from the SIOPE Host Genome Working Group.

Authors:  Simone Hettmer; Guillaume Dachy; Guido Seitz; Abbas Agaimy; Catriona Duncan; Marjolijn Jongmans; Steffen Hirsch; Iris Kventsel; Uwe Kordes; Ronald R de Krijger; Markus Metzler; Orli Michaeli; Karolina Nemes; Anna Poluha; Tim Ripperger; Alexandra Russo; Stephanie Smetsers; Monika Sparber-Sauer; Eveline Stutz; Franck Bourdeaut; Christian P Kratz; Jean-Baptiste Demoulin
Journal:  Fam Cancer       Date:  2020-09-05       Impact factor: 2.375

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.